Accumulated Clinical Experience across Four International Studies Highlighted in Two Presentations at World IDF Congress
GI Dynamics, Inc. (ASX: GID) today announced findings from a new meta-analysis which describes the increasingly robust efficacy and safety profile of EndoBarrier® Therapy, an endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. The findings, which were presented today at the International Diabetes Federation’s World Diabetes Congress in Melbourne, Australia, add to the growing body of clinical evidence supporting the use of EndoBarrier Therapy for patients with type 2 diabetes and obesity.
“The progressive nature of type 2 diabetes and obesity poses a significant and growing challenge in clinical practice, and current therapies often do not provide optimal solutions for many patients,” said David Maggs, chief medical officer of GI Dynamics, and lead author of the study. “Medical devices such as EndoBarrier represent an exciting class of therapy that can help bridge the gap between pharmaceuticals, which may become less effective over time, and bariatric surgery, which can be effective, however, requires irreversible anatomical changes. These new meta-analysis data further support the strong safety profile and robust efficacy of EndoBarrier Therapy in the management of type 2 diabetes and obesity.”
In an oral presentation titled, “Endoscopic, Duodenal-Jejunal Bypass Liner Exerts Robust Metabolic Effects: Accumulating Clinical Experience Across Four Studies,” results from four prospective, single-arm studies were shared involving a total of 130 patients from three countries implanted with EndoBarrier for a planned 12-month duration. Across all studies, the metabolic effects of EndoBarrier Therapy were robust and well established early in the treatment period. Key findings include: